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ABSTRACT
Background Amylase and lipase, pancreatic biomarkers, are measured in acute 
pancreatitis diagnosis. Since amylase testing does not add diagnostic value, lipase 
testing alone is recommended. Despite new recommendations, many physicians 
and staff continue to test both amylase and lipase.
Objective To reduce unnecessary diagnostic testing in acute pancreatitis.
Methods The pre-checked amylase test within the Emergency Department’s 
Computerised Provider Order Entry (CPOE) abdominal pain order set was changed 
to an un-checked state but kept as an option to order with a single click. Amylase test-
ing, lipase testing and cost were measured for one year pre- and post-intervention. 
Results Simple de-selection intervention reduced redundant amylase testing 
from 71% to 9%, resulting in a percent of decrease of 87% and an annualised sav-
ing of approximately $719,000 in charges.
Conclusion CPOE de-selection is an effective tool to reduce non-value added 
activity and reduce cost while maintaining quality patient care and physician choice.
Keywords:  amylase, cost analysis, computerised physician order entry 
system
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INTRODUCTION
The purpose of this study was to reduce utilization of amylase 
testing as a redundant biomarker in diagnosing pancreatitis 
to improve patient care and reduce institutional cost while 
minimizing the effect on physician choice. Acute pancreati-
tis hospitalizations in the United States cost $2.2 billion in 
2003, averaging $9,870 per patient.1 Acute pancreatitis is 
diagnosed when abdominal pain is present, serum amylase 
and/or lipase levels are elevated, and/or abdominal imaging 
meets the diagnosis criteria. Amylase and lipase, common 
pancreatic biomarkers, are released after the initial onset 
of acute pancreatitis and are commonly measured upon 
hospitalization.2
Amylase levels increase 3–6 hours after pancreatitis ini-
tiation and remain elevated for 3–5 days. Although high 
serum amylase levels can be reflective of pancreatic inflic-
tion, levels are also high in patients with gastroenteritis 
and acute liver failure. In addition, it is not uncommon for 
amylase levels to be within normal range in patients with 
acute pancreatitis. Lipase levels increase 3–6 hours after 
pancreatitis initiation but remain elevated for 1–2 weeks. 
Elevated serum lipase levels have also been reported in 
patients with non-pancreatic abdominal pain and other 
conditions.2
Previously, both amylase and lipase analyses were 
recommended in pancreatitis diagnostic testing. More 
recently, lipase testing alone was recommended since 
lipase testing is more specific and amylase testing does 
not add diagnostic value. Furthermore, since amylase 
levels fall back within the normal range more quickly than 
lipase levels following acute pancreatitis, lipases have an 
extended window available for biomarker measurement 
and analysis.2 Despite the new recommendations, many 
physicians and staff continue to test both amylase and 
lipase in pancreatitis diagnosis. To promote the recom-
mended change, institutions have implicated educational 
interventions and removal of amylase testing from com-
puter ordering systems to decrease amylase test order-
ing in Emergency Departments (ED), decreasing patient 
charges.3 Therefore, our goal was to alter the computer 
order entry in the ED to reduce utilization of amylase test-
ing as a redundant biomarker in diagnosing pancreatitis 
without eliminating the physicians’ option to utilise amylase 
testing if desired. We hypothesized that altered computer 
order entry would increase value for our patients by reduc-
ing unnecessary utilization of diagnostic testing.
METHODS
This study was reviewed by our local Institutional Review 
Board and determined Non-Human Subjects Research, 
Reference #: 012633. Computerized Provider Order Entry 
(CPOE) process interventions and a modified Lean Six 
Sigma method were used to reduce non-essential steps 
and improve quality. The CPOE change was functionally 
simple; the pre-checked amylase test in the ED order set 
for abdominal pain was changed to an un-checked state. 
The decision was made to leave amylase available in the 
order sets. If the physician wanted to include the test, they 
could simply recheck it. Baseline measurements of amy-
lase and lipase testing were determined from January-
December 2014, preceding the CPOE change, using the 
Cerner Discern Analytics program. Post-intervention, 
orders for amylase and lipase testing were measured from 
January-December 2015, the same months as the base-
line measurements the previous year. Sustainability of 
change was followed through June 2016. Charges to per-
form amylase testing were calculated from the institution’s 
Cost Accounting System. Minitab was used to evaluate the 
statistical significance of the intervention using a 2-tailed 
t-test, *p<0.0001.
RESULTS
Our frontline physician leaders optimized the CPOE 
through the Test Utilization Committee and stakeholders 
to facilitate evidence-based ordering practice. In 2014, 
10,843 ED patients had orders for a lipase test. Of those 
patients, 7,647 had simultaneous orders for amylase. The 
charge to the organization to perform an amylase test was 
$109.00 per order. Because amylase was tested simul-
taneously with lipase 71% of the time, the opportunity 
for organizational charge reduction was approximately 
$834,000 annually simply by removing or limiting a non-
value added test (Table 1).
The simultaneous testing of amylase with lipase was 
measured during the same months in 2015 post-interven-
tion. Simple de-selection intervention reduced redundant 
amylase testing from 71% to 9%, resulting in a percent 
of decrease of 87% in co-ordered testing (Table 1). Since 
the amylase test charge was $109/test, a mean charge of 
$2,283/day was determined pre-intervention. In 2015, post-
intervention, amylase orders/day mean declined from 21 
to 2.8 with charges dropping to a mean $313/day with an 
annualized saving of approximately $719,000 (Table 1). 
Monthly lipase and amylase testing was compared pre- 
and post-intervention. Reduction in amylase utilization was 
maintained post-intervention through June 2016 (Figure 1). 
To ensure our patients received quality care, we measured 
3 and 30 day revisit rates for ED patients presenting with 
abdominal pain during the pre- and post-intervals. There 
were no significant differences in revisit rates. No harm 
in unchecking amylase was identified. No physician com-
plaints resulted from the change.
DISCUSSION
Physician driven structural changes in our CPOE reduced 
unnecessary amylase testing by 87%. By simply un-check-
ing the amylase test in the ED order set, financial burden 
to patients and payer was lessened and charge to the 
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system was reduced while maintaining quality patient care. 
In 2014, Thomas Jefferson University Hospital removed 
amylase from common order sets in the electronic medical 
record. Co-ordering of amylase and lipase decreased by 
15.2% and with an average Medicare charge of $35/test, 
patient charges were reduced approximately $135,000/
year.4 Additionally, in 2010, a trauma centre introduced an 
educational intervention, deletion of amylase from trauma 
order forms, and decoupled amylase and lipase in their 
computer ordering system. This effectively reduced co-
ordering of amylase and lipase from 93% to 14.3% and 
decreased patient’s charges approximately $350,000/
year.3 Our institution has previously been successful in 
reducing diagnostic testing with the cardiac biomarker cre-
atine kinase-muscle and brain-type isoenzyme in acute 
myocardial infarction diagnosis through de-selection within 
the CPOE system.5
CPOE guides appropriate diagnostic testing choices. 
Although removing diagnostic tests from CPOE order 
forms is a successful strategy, it impacts physician free-
dom of practice. For example, Volz et al.3 removed the 
option to choose amylase on the order form, and amylase 
could only be ordered if specifically added. Additionally, 
Barbieri et al.4 removed amylase from order set forms, lim-
iting amylase ordering to ad-hoc situations. Other institu-
tions allow physicians to override reminders of redundant 
Figure 1. Sustainable reduction in redundant diagnostic testing through CPOE de-selection. Unchecking amylase from 
the CPOE abdominal pain order set significantly reduced unnecessary diagnostic testing, sustainable for 18 months 
post-intervention
testing and continue with their desired orders, a freedom 
that is thought to correlate with physician satisfaction with 
the electronic ordering system.6 Our design was unique in 
which amylase testing was not removed from CPOE order 
sets, only unchecked. Simply unchecking amylase was 
successful in reducing redundant diagnostic testing with-
out eliminating physician’s choice.
A limitation of this study was that only minor changes 
were made within the CPOE system at a single institu-
tion; therefore, results cannot be generalized to extensive 
conclusions. However minor the adjustments may seem, 
small accumulative changes promote significant changes 
over time. Moving forward, assessments of redundant 
laboratory testing will continue to be evaluated and Lean 
Six Sigma methods will be utilized to further reduce insti-
tutional cost.
CONCLUSION
We have demonstrated that the simple unchecking of a 
non-value added test can result in considerable savings 
while preserving physician choice.
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